ITeos Therapeutics (NAS:ITOS) Growth Rank

: 0 (As of Today)

View and export this data going back to 2020. Start your Free Trial

ITeos Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

ITeos Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of ITeos Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

ITeos Therapeutics (NAS:ITOS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ITeos Therapeutics Inc (NAS:ITOS) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Arsenal Street, Watertown, MA, USA, 02472

Website

https://www.iteostherapeutics.com

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.

Executives

Joseph Lewis	other: See remarks	PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc.	other: See remarks	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis	other: See remarks	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Tony W Ho	director	CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Robert Iannone	director	300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Matthew Roden	director	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014 Gp Llc	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p.	10 percent owner	C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Derek Dirocco	director	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Mpm Bioventures 2018 (b), L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Asset Management Investors Bv2018 Llc	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2018 Gp Llc	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142